REGENXBIO (RGNX)
(Delayed Data from NSDQ)
$9.59 USD
+0.41 (4.47%)
Updated Nov 22, 2024 04:00 PM ET
After-Market: $9.61 +0.02 (0.21%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RGNX 9.59 +0.41(4.47%)
Will RGNX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for RGNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RGNX
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates
Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet
RGNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates
Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
Other News for RGNX
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Regenxbio price target lowered to $36 from $40 at H.C. Wainwright
Buy Rating on RegenXBio Driven by Positive RGX-202 Trial Results and Strong Approval Prospects
Regenxbio price target lowered by $4 at H.C. Wainwright, here's why